Unique Relationship Between FDA and Biogen Brings Scrutiny and Pharma Envy

As the controversy surrounding the relationship between Biogen and the FDA continues, pharmaceutical companies are trying to determine how Biogen managed to secure such close ties with the FDA. The FDA’s Billy Dunn is facing substantial interest for his role in Biogen’s Aduhelm approval.

“As the saga over how to pay for Aduhelm plays out, biopharma companies are now looking closely at how Biogen was able to keep such a special relationship with FDA officials ahead of the drug’s accelerated approval, and whether or not they might be able to leverage those takeaways into their own relationships with the agency.” Read more here.

(Source: Zachary Brennan, Endpoints News, 7/21/21)